The number of people who have recuperated from the disease surged to 96,06,111, pushing the national recovery rate to 95.53 per cent, while the COVID-19 case fatality rate stands at 1.45 per cent, according to the data.
The death toll climbed to 5,02,874 with 895 more fatalities, the data updated at 8 am stated.
India's COVID-19 tally rose to 1,11,92,088 with over 18,000 fresh cases being reported in a span of 24 hours in the country after 36 days, while active cases registered an increase for the fourth consecutive day on Saturday and were recorded at 1,80,304, according to the Union health ministry.
The productivity of the Budget session was abysmal. The Lok Sabha functioned for 33% of its scheduled time (46 hours); the Rajya Sabha 24% (32 hours).
In this exclusive interview with Rediff.com's Shobha Warrier from Jaipur, Dr Gupta talks about the study and what the urban population to do to fight hypertension.
Bihar Chief Minister Nitish Kumar on Wednesday apologised in both Houses of the legislature, as well as outside, for remarks made a day before on the importance of women's education to control population growth.
The active cases comprise 1.03 per cent of the total infections while the national COVID-19 recovery rate was recorded at 97.63 per cent, the ministry said.
The number of active coronavirus cases in the country has surpassed the 16-lakh mark, the ministry's data updated at 8 am showed.
The death toll has climbed to 4,89,848 with 439 fresh fatalities, the data updated at 8 am stated.
A total of 1,59,632 new coronavirus infections were reported in a day, the highest in 224 days.
There has been a 4.36 per cent increase in Omicron cases since Thursday, the ministry said.
India logged 36,571 new coronavirus infections, taking the total tally of Covid-19 cases to 3,23,58,829, while the national recovery rate improved to 97.54 per cent, the highest since March 2020, according to the Union health ministry data updated on Friday.
The number of people who have recuperated from the disease has gone up to 4,24,85,534.
The number of new coronavirus cases in India hit a record daily high since the outbreak of the pandemic with over 1.15 lakh new infections being reported in a span of 24 hours, pushing the nationwide COVID-19 tally to 1,28,01,785, according to the Union health ministry data updated on Wednesday.
According to sources, so far only one traveller from Canada having symptoms of monkeypox infection had been isolated.
India saw a single-day rise of 38,667 coronavirus infections, taking the total tally of cases to 3,21,56,493, while the death toll rose to 4,30,732 with 478 fresh fatalities, according to the Union health ministry data updated Saturday.
The tally of active cases now comprises 0.05 per cent of the total infections.
In a tweet, Deputy Chief Minister Manish Sisodia said, "7,040 people underwent rapid-antigen test at 193 centres across Delhi. Of this, 456 people have been found positive."
The second wave is expected based on what is happening in Europe, the govt said.
Registering a steady increase for the 18th day in row, the active cases have increased to 4,86,310 comprising 4.06 per cent of the total infections, while the recovery rate has further dropped to 94.58 per cent, the data stated.
The number of people who have recuperated from the disease surged to 3,10, 99,771, while the case fatality rate stands at 1.34 per cent.
A total of 76,56,478 people have recuperated from the infection so far, pushing the national recovery rate to 92.09 per cent, while the case fatality rate stands at 1.49 per cent.
India's COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23 and 40 lakh on September 5. It went past 50 lakh on September 16, 60 lakh on September 28, 70 lakh on October 11 and crossed 80 lakh on October 29.
The most important finding of the study was that the Spike-protein neutralising antibodies found in the mixed vaccine groups were significantly higher than the same-vaccine groups, D Nageshwar Reddy, Chairman of AIG Hospitals said.
Officials said several witnesses were heard on the impact of the pandemic. They added that this was the longest meeting of the panel without a break so far.
All COVID vaccines do not prevent infection and are primarily disease-modifying, said Dr Balram Bhargava, director general, Indian Council of Medical Research on Thursday.
There are 6,68,154 active cases of COVID-19 in the country as on date which comprise 8.50 per cent of the total caseload, the data stated.
The Rhesus macaque monkeys, used worldwide in medical research, are believed to be the best non-human primates for such studies.
There are now 1,348 testing labs in the country comprising 914 in the public sector and 434 private labs.
ICMR Director General said some studies have suggested that antibodies last for three months while some others said they may last in the body for up to five months also.
There are 7,72,055 active cases of coronavirus infection in the country which comprises 10.23 per cent of the total caseload, the data stated.
After reports of contamination in cough syrups sent from the country, India is considering a system to test them before exporting. It is learnt that the Central Drugs Standard Control Organisation (CDSCO) has sent a proposal to the Union health ministry on this. The idea is to test the medicines at government labs before exporting.
The active cases have declined to 4,24,025 and comprise 1.36 per cent of the total infections.
'Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,' says the volunteer's advocate.
With 8,439 more people testing positive for COVID-19 in a day, India's infection tally rose to 3,46,56,822 on Wednesday, while the count of active cases declined to 93,733, the lowest in 555 days, according to the Union Health Ministry data.
Covaxin is being developed by Bharat Biotech jointly with the Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV). The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the country's first and only Phase III efficacy study for a COVID-19 vaccine, a press release from the vaccine maker said on Saturday night.
When several opposition MPs expressed their desire to ask questions about the Centre's vaccination policy such as increasing the gap between two doses, the BJP MPs strongly opposed it and few of them even demanded postponement of the meeting and walked out, the sources said.
'This week will be crucial and we are prepared.'
The Union health ministry on Wednesday dismissed media reports claiming there was dissent from technical experts about increasing the gap between two Covishield doses and said the decision was based on scientific reason about the behaviour of adenovector vaccines.
